459 related articles for article (PubMed ID: 31122894)
1. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial.
Sivapalan P; Lapperre TS; Janner J; Laub RR; Moberg M; Bech CS; Eklöf J; Holm FS; Armbruster K; Sivapalan P; Mosbech C; Ali AKM; Seersholm N; Wilcke JT; Brøndum E; Sonne TP; Rønholt F; Andreassen HF; Ulrik CS; Vestbo J; Jensen JS
Lancet Respir Med; 2019 Aug; 7(8):699-709. PubMed ID: 31122894
[TBL] [Abstract][Full Text] [Related]
2. Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.
Ramakrishnan S; Jeffers H; Langford-Wiley B; Davies J; Thulborn SJ; Mahdi M; A'Court C; Binnian I; Bright S; Cartwright S; Glover V; Law A; Fox R; Jones A; Davies C; Copping D; Russell RE; Bafadhel M
Lancet Respir Med; 2024 Jan; 12(1):67-77. PubMed ID: 37924830
[TBL] [Abstract][Full Text] [Related]
3. A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations - The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol.
Sivapalan P; Moberg M; Eklöf J; Janner J; Vestbo J; Laub RR; Browatzki A; Armbruster K; Wilcke JT; Seersholm N; Weinreich UM; Titlestad IL; Andreassen HF; Ulrik CS; Bødtger U; Nielsen TL; Hansen EF; Jensen JUS
BMC Pulm Med; 2017 Aug; 17(1):114. PubMed ID: 28810909
[TBL] [Abstract][Full Text] [Related]
4. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.
Walters JA; Tan DJ; White CJ; Wood-Baker R
Cochrane Database Syst Rev; 2014 Dec; (12):CD006897. PubMed ID: 25491891
[TBL] [Abstract][Full Text] [Related]
5. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.
Walters JA; Tan DJ; White CJ; Wood-Baker R
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD006897. PubMed ID: 29553157
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Rabe KF; Watz H; Baraldo S; Pedersen F; Biondini D; Bagul N; Hanauer G; Göhring UM; Purkayastha D; Román J; Alagappan VKT; Saetta M
Lancet Respir Med; 2018 Nov; 6(11):827-836. PubMed ID: 30224319
[TBL] [Abstract][Full Text] [Related]
7. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
[TBL] [Abstract][Full Text] [Related]
8. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.
Hastie AT; Martinez FJ; Curtis JL; Doerschuk CM; Hansel NN; Christenson S; Putcha N; Ortega VE; Li X; Barr RG; Carretta EE; Couper DJ; Cooper CB; Hoffman EA; Kanner RE; Kleerup E; O'Neal WK; Paine R; Peters SP; Alexis NE; Woodruff PG; Han MK; Meyers DA; Bleecker ER;
Lancet Respir Med; 2017 Dec; 5(12):956-967. PubMed ID: 29146301
[TBL] [Abstract][Full Text] [Related]
9. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
10. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.
van Velzen P; Ter Riet G; Bresser P; Baars JJ; van den Berg BTJ; van den Berg JWK; Brinkman P; Dagelet JWF; Daniels JMA; Groeneveld-Tjiong DRGL; Jonkers RE; van Kan C; Krouwels FH; Pool K; Rudolphus A; Sterk PJ; Prins JM
Lancet Respir Med; 2017 Jun; 5(6):492-499. PubMed ID: 28483402
[TBL] [Abstract][Full Text] [Related]
11. Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials.
Sivapalan P; Rutishauser J; Ulrik CS; Leuppi JD; Pedersen L; Mueller B; Eklöf J; Biering-Sørensen T; Gottlieb V; Armbruster K; Janner J; Moberg M; Lapperre TS; Nielsen TL; Browatzki A; Mathioudakis A; Vestbo J; Schüetz P; Jensen JU
Respir Res; 2021 May; 22(1):155. PubMed ID: 34020641
[TBL] [Abstract][Full Text] [Related]
12. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.
Walters JA; Wang W; Morley C; Soltani A; Wood-Baker R
Cochrane Database Syst Rev; 2011 Oct; (10):CD006897. PubMed ID: 21975757
[TBL] [Abstract][Full Text] [Related]
13. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
[TBL] [Abstract][Full Text] [Related]
14. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM
Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
[TBL] [Abstract][Full Text] [Related]
15. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.
Heaney LG; Busby J; Hanratty CE; Djukanovic R; Woodcock A; Walker SM; Hardman TC; Arron JR; Choy DF; Bradding P; Brightling CE; Chaudhuri R; Cowan DC; Mansur AH; Fowler SJ; Niven RM; Howarth PH; Lordan JL; Menzies-Gow A; Harrison TW; Robinson DS; Holweg CTJ; Matthews JG; Pavord ID;
Lancet Respir Med; 2021 Jan; 9(1):57-68. PubMed ID: 32916135
[TBL] [Abstract][Full Text] [Related]
16. Multicentre double-blind randomised controlled trial of systematic corticosteroid therapy in patients with acute exacerbations of chronic obstructive pulmonary disease admitted to hospital with higher eosinophil levels: the ECHO protocol.
Liang L; Lin Y; Feng L; Shao S; Cao S; Rong H; Chu S; Xie W; Cai S; Wang J; Tong Z
BMJ Open; 2023 May; 13(5):e066354. PubMed ID: 37247957
[TBL] [Abstract][Full Text] [Related]
17. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
18. Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial).
Urwyler P; Boesing M; Abig K; Cattaneo M; Dieterle T; Zeller A; Bachler H; Markun S; Senn O; Merlo C; Essig S; Ullmer E; Rutishauser J; Schuurmans MM; Leuppi JD
Trials; 2019 Dec; 20(1):727. PubMed ID: 31842993
[TBL] [Abstract][Full Text] [Related]
19. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial.
Bafadhel M; McKenna S; Terry S; Mistry V; Pancholi M; Venge P; Lomas DA; Barer MR; Johnston SL; Pavord ID; Brightling CE
Am J Respir Crit Care Med; 2012 Jul; 186(1):48-55. PubMed ID: 22447964
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.
de Jong E; van Oers JA; Beishuizen A; Vos P; Vermeijden WJ; Haas LE; Loef BG; Dormans T; van Melsen GC; Kluiters YC; Kemperman H; van den Elsen MJ; Schouten JA; Streefkerk JO; Krabbe HG; Kieft H; Kluge GH; van Dam VC; van Pelt J; Bormans L; Otten MB; Reidinga AC; Endeman H; Twisk JW; van de Garde EMW; de Smet AMGA; Kesecioglu J; Girbes AR; Nijsten MW; de Lange DW
Lancet Infect Dis; 2016 Jul; 16(7):819-827. PubMed ID: 26947523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
